D
Cardiff Oncology, Inc.
CRDF
$3.94
-$0.21-5.06%
D
Sell
3/1/2024Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 3/1/2024 due to an increase in the total return index and volatility index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 3/1/2024 due to an increase in the total return index and volatility index.
E
Sell
2/13/2024Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 2/13/2024 due to a decline in the total return index, volatility index and growth index.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 2/13/2024 due to a decline in the total return index, volatility index and growth index.
D
Sell
1/25/2024Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index and total return index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 1/25/2024 due to an increase in the volatility index and total return index.
E
Sell
1/9/2024Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index and valuation index.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 1/9/2024 due to a decline in the volatility index and valuation index.
D
Sell
12/18/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 12/18/2023 due to an increase in the total return index and volatility index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 12/18/2023 due to an increase in the total return index and volatility index.
E
Sell
12/1/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 12/1/2023 due to a decline in the total return index and volatility index.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 12/1/2023 due to a decline in the total return index and volatility index.
D
Sell
11/10/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 11/10/2023 due to an increase in the growth index and volatility index. Total revenue increased 30.56% from $108 to $141, earnings per share increased from -$0.25 to -$0.2179, and EBIT increased 11.37% from -$12.21M to -$10.82M.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 11/10/2023 due to an increase in the growth index and volatility index. Total revenue increased 30.56% from $108 to $141, earnings per share increased from -$0.25 to -$0.2179, and EBIT increased 11.37% from -$12.21M to -$10.82M.
E
Sell
10/26/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 10/26/2023 due to a decline in the volatility index and total return index.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 10/26/2023 due to a decline in the volatility index and total return index.
D
Sell
8/31/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index and total return index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 8/31/2023 due to an increase in the volatility index and total return index.
E
Sell
8/15/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 11.98 to 9.82.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 8/15/2023 due to a decline in the volatility index and solvency index. The quick ratio declined from 11.98 to 9.82.
D
Sell
8/7/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 8/7/2023 due to an increase in the volatility index and total return index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 8/7/2023 due to an increase in the volatility index and total return index.
E
Sell
7/21/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 7/21/2023 due to a decline in the total return index and volatility index.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 7/21/2023 due to a decline in the total return index and volatility index.
D
Sell
7/6/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 7/6/2023 due to an increase in the volatility index.
E
Sell
6/16/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 6/16/2023 due to a decline in the total return index and volatility index.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 6/16/2023 due to a decline in the total return index and volatility index.
D
Sell
5/30/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 5/30/2023 due to an increase in the volatility index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D- from E+ on 5/30/2023 due to an increase in the volatility index.
E
Sell
5/12/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index, growth index and solvency index. Total revenue declined 35.16% from $128 to $83, EBIT declined 28.32% from -$9.39M to -$12.05M, and earnings per share declined from -$0.1989 to -$0.2513.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D- on 5/12/2023 due to a decline in the volatility index, growth index and solvency index. Total revenue declined 35.16% from $128 to $83, EBIT declined 28.32% from -$9.39M to -$12.05M, and earnings per share declined from -$0.1989 to -$0.2513.
D
Sell
3/14/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and growth index. Operating cash flow declined 25.43% from -$7.49M to -$9.39M, EBIT declined 4.44% from -$8.99M to -$9.39M, and the quick ratio declined from 13.94 to 13.58.
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index and growth index. Operating cash flow declined 25.43% from -$7.49M to -$9.39M, EBIT declined 4.44% from -$8.99M to -$9.39M, and the quick ratio declined from 13.94 to 13.58.
D
Sell
2/23/2023Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and total return index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and total return index.
D
Sell
2/8/2023Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 02/08/2023.
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 02/08/2023.
D
Sell
8/8/2022Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 8/8/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 34.68% from -$10.25M to -$6.7M, total revenue increased 22.97% from $74 to $91, and EBIT increased 5.7% from -$11.07M to -$10.44M.
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 8/8/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 34.68% from -$10.25M to -$6.7M, total revenue increased 22.97% from $74 to $91, and EBIT increased 5.7% from -$11.07M to -$10.44M.
D
Sell
8/3/2022Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 8/3/2022 due to a decline in the volatility index.
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 8/3/2022 due to a decline in the volatility index.
D
Sell
7/15/2022Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 7/15/2022 due to an increase in the volatility index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 7/15/2022 due to an increase in the volatility index.
D
Sell
6/21/2022Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 6/21/2022 due to a large decline in the total return index, volatility index and valuation index.
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 6/21/2022 due to a large decline in the total return index, volatility index and valuation index.
D
Sell
5/16/2022Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D from E+ on 05/16/2022.
Cardiff Oncology, Inc. (CRDF) was upgraded to D from E+ on 05/16/2022.
E
Sell
5/13/2022Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Total revenue declined 44.36% from $133 to $74, operating cash flow declined 38.69% from -$7.39M to -$10.25M, and EBIT declined 16.25% from -$9.53M to -$11.07M.
Cardiff Oncology, Inc. (CRDF) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, solvency index and volatility index. Total revenue declined 44.36% from $133 to $74, operating cash flow declined 38.69% from -$7.39M to -$10.25M, and EBIT declined 16.25% from -$9.53M to -$11.07M.
D
Sell
5/5/2022Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 36.12% from -$7M to -$9.53M, operating cash flow declined 35.22% from -$5.47M to -$7.39M, and earnings per share declined from -$0.1749 to -$0.2327.
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 4/20/2022 due to a decline in the growth index, total return index and volatility index. EBIT declined 36.12% from -$7M to -$9.53M, operating cash flow declined 35.22% from -$5.47M to -$7.39M, and earnings per share declined from -$0.1749 to -$0.2327.
D
Sell
11/23/2021Upgraded
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
Cardiff Oncology, Inc. (CRDF) was upgraded to D from D- on 11/23/2021 due to an increase in the valuation index.
D
Sell
11/8/2021Downgrade
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 27.06% from -$4.3M to -$5.47M, EBIT declined 1.58% from -$6.89M to -$7M, and earnings per share declined from -$0.1745 to -$0.1749.
Cardiff Oncology, Inc. (CRDF) was downgraded to D- from D on 11/8/2021 due to a major decline in the growth index and valuation index. Operating cash flow declined 27.06% from -$4.3M to -$5.47M, EBIT declined 1.58% from -$6.89M to -$7M, and earnings per share declined from -$0.1745 to -$0.1749.
D
Sell
5/1/2020Upgraded
TrovaGene, Inc. (TROV) was upgraded to D from E+ on 5/1/2020 due to a noticeable increase in the growth index, solvency index and volatility index. Total revenue increased 79.11% from $51.7 to $92.6, earnings per share increased from -$0.7123 to -$0.5123, and debt to equity declined from 0.13 to 0.12.
TrovaGene, Inc. (TROV) was upgraded to D from E+ on 5/1/2020 due to a noticeable increase in the growth index, solvency index and volatility index. Total revenue increased 79.11% from $51.7 to $92.6, earnings per share increased from -$0.7123 to -$0.5123, and debt to equity declined from 0.13 to 0.12.
E
Sell
11/12/2019Downgrade
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 11/12/2019 due to a decline in the growth index, efficiency index and solvency index. Total revenue declined 62.62% from $138.3 to $51.7, debt to equity increased from 0.09 to 0.13, and the quick ratio declined from 2.95 to 2.2.
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 11/12/2019 due to a decline in the growth index, efficiency index and solvency index. Total revenue declined 62.62% from $138.3 to $51.7, debt to equity increased from 0.09 to 0.13, and the quick ratio declined from 2.95 to 2.2.
D
Sell
8/19/2019Upgraded
TrovaGene, Inc. (TROV) was upgraded to D- from E+ on 8/19/2019 due to an increase in the efficiency index, total return index and volatility index.
TrovaGene, Inc. (TROV) was upgraded to D- from E+ on 8/19/2019 due to an increase in the efficiency index, total return index and volatility index.
E
Sell
8/3/2018Downgrade
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 8/3/2018 due to a decline in the volatility index, growth index and efficiency index. Operating cash flow declined 13.81% from -$2.86M to -$3.25M.
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 8/3/2018 due to a decline in the volatility index, growth index and efficiency index. Operating cash flow declined 13.81% from -$2.86M to -$3.25M.
D
Sell
2/27/2018Upgraded
TrovaGene, Inc. (TROV) was upgraded to D- from E+ on 2/27/2018 due to a noticeable increase in the growth index, solvency index and efficiency index. Total revenue increased 50.04% from $123.3 to $185, operating cash flow increased 49.48% from -$6.59M to -$3.33M, and debt to equity declined from 0.38 to 0.2.
TrovaGene, Inc. (TROV) was upgraded to D- from E+ on 2/27/2018 due to a noticeable increase in the growth index, solvency index and efficiency index. Total revenue increased 50.04% from $123.3 to $185, operating cash flow increased 49.48% from -$6.59M to -$3.33M, and debt to equity declined from 0.38 to 0.2.
E
Sell
1/30/2018Downgrade
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 1/30/2018 due to a decline in the volatility index and total return index.
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 1/30/2018 due to a decline in the volatility index and total return index.
D
Sell
12/19/2017Upgraded
TrovaGene, Inc. (TROV) was upgraded to D- from E+ on 12/19/2017 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.26 to -$0.12, the quick ratio increased from 1.06 to 1.5, and total revenue increased 20.88% from $102 to $123.3.
TrovaGene, Inc. (TROV) was upgraded to D- from E+ on 12/19/2017 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from -$0.26 to -$0.12, the quick ratio increased from 1.06 to 1.5, and total revenue increased 20.88% from $102 to $123.3.
E
Sell
8/10/2017Downgrade
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 8/10/2017 due to a noticeable decline in the volatility index, solvency index and total return index. The quick ratio declined from 3.22 to 1.06.
TrovaGene, Inc. (TROV) was downgraded to E+ from D- on 8/10/2017 due to a noticeable decline in the volatility index, solvency index and total return index. The quick ratio declined from 3.22 to 1.06.
D
Sell
5/11/2016Downgrade
TrovaGene, Inc. (TROV) was downgraded to D- from D on 5/11/2016 due to a decline in the growth index, solvency index and efficiency index. EBIT declined 41.64% from -$7.38M to -$10.46M, earnings per share declined from -$0.2575 to -$0.36, and net income declined 39.04% from -$7.38M to -$10.26M.
TrovaGene, Inc. (TROV) was downgraded to D- from D on 5/11/2016 due to a decline in the growth index, solvency index and efficiency index. EBIT declined 41.64% from -$7.38M to -$10.46M, earnings per share declined from -$0.2575 to -$0.36, and net income declined 39.04% from -$7.38M to -$10.26M.
D
Sell
4/14/2016Upgraded
TrovaGene, Inc. (TROV) was upgraded to D from D- on 4/14/2016 due to an increase in the volatility index, valuation index and total return index.
TrovaGene, Inc. (TROV) was upgraded to D from D- on 4/14/2016 due to an increase in the volatility index, valuation index and total return index.
D
Sell
3/11/2016Downgrade
TrovaGene, Inc. (TROV) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 10.65 to 8.24, and debt to equity increased from 0.28 to 0.34.
TrovaGene, Inc. (TROV) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 10.65 to 8.24, and debt to equity increased from 0.28 to 0.34.
NASDAQ
03/13/2025 12:48PM Eastern
Quotes delayed
